-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
We keep our 12-month target price of $340, 8.3x our 2027 operating EPS of $41.20 and 8.4x our 2026 EPS of $40.56 (raised by $3.21), versus the three-year average forward multiple of 8.1x and a peer average of 9x. RNR posted Q1 operating EPS of $13.75 versus an operating loss of $1.49 a year ago, beating our $7.54 estimate and the $11.22 consensus on improved underwriting profitability. Operating revenues declined 17% Y/Y to $2.6B, lagging our forecast, reflecting a nearly 20% drop in earned premiums. Underwriting results improved with Q1 underwriting profit of $588.8M vs. a $770.6M loss, with the combined ratio improving to 73.0% from 128.3%. Net written premiums declined over 22% in Q1 to under $2.7B, as RNR trims underwriting amid softening prices. We don't see the Q1 production (or lack thereof) as a run rate, but we lower our revenue forecast to flat to down 7% in 2026. At current levels, the shares trade at 7.4x our 2026 EPS, below our target valuation and undervalued vs. peer and historical averages.